Neuroendocrine differentiation after neoadjuvant hormonal treatment in prostate cancer

Minerva Urologica e Nefrologica

Volumn 57, Issue 4, 2005, Pages 319-324

  Autorino, R ^a,e   Di Lorenzo, G ^b   D'Armiento, F P ^b   Mignogna, C ^b   Cindolo, L ^c   De Sio, M ^a   Perdona, S ^d   De Fortuna, E ^c   Salzano, L ^c   De Placido, S ^b   D'Armiento, M ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c G RUMMO HOSPITAL   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e FEBU   (Italy)

Author keywords

Neoadjuvant hormonal therapy; Neuroendocrine differentiation; Prostatic neoplasms; Radical prostatectomy

Indexed keywords

BICALUTAMIDE; CHROMOGRANIN A; LEUPRORELIN; MONOCLONAL ANTIBODY;

ANTIBODY SPECIFICITY; ARTICLE; BIOCHEMISTRY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RELAPSE; CELL DIFFERENTIATION; CONTROLLED STUDY; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; NEUROENDOCRINE SYSTEM; PROSTATE CANCER; PROSTATECTOMY; STAINING; TUMOR CELL;

ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; HUMANS; MALE; NEUROSECRETORY SYSTEMS; PROSTATIC NEOPLASMS;

EID: 28544433368     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Abrahamsson PA. Neuroendocrine differentiation and hormone-refractory prostate cancer. Prostate Suppl 1996;6:3-8.
2. Jiborn T, Bjartell A, Abrahamsson PA. Neuroendocrine differentation in prostatic carcinoma during hormonal treatment. Urology 1998;51:585-9.
3. Di Sant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic and therapeutic implications. Cancer 1992;70:254-68.
4. Kollermann J, Helpap B. Neuroendocrine differentiation and short-term neoadjuvant hormonal treatment of prostatic carcinoma with special regard to tumor regression. Eur Urol 2001;40:313-7.
5. Ahlgren G, Pedersen K, Lundberg S, Aus G, Hugosson J, Abrahamsson PA. Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume. Urology 2000;56: 1011-5.
6. Reuter VE. Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology 1997;49 Suppl 3A:16-22.
7. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001;165:1146-51.
8. Hammad Ather M, Abbas F. Prognostic significance of neuroendocrine differentiation in prostate cancer. Eur Urol 2000;38:535-42.
9. Bostwick DG, Qian J, Pacelli A, Zincke H, Blute M, Bergstralh EJ et al. Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival. J Urol 2002;168:1204-11.
10. Kokubo H, Yamada Y, Nishio Y, Fukatsu H, Honda N, Nakagawa A et al. Himmunohistochemical study of chromogranin A in stage D2 prostate cancer. Urology 2005;66:135-40.
11. Cohen RJ, Glezerson G, Haffejee Z. Neuro-endocrine cells: a new prognostic parameter in prostate cancer. Br J Urol 1991;68:258-62.
12. Allen FJ, van Velden DJJ, Heyns CF. Are neuroendocrine cells of practical value as an indipendent prognostic parameter in prostate cancer? Br J Urol 1995;75:751-4.
13. Aprikian AG, Cordon-Cardo C, Fair WR, Reuter VE. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 1993;71:3952-65.
14. Krijnen JL, Janssen PJ, Ruizeveld de Winter JA, van Krimpen H, Schroder FH, van der Kwast TH. Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry 1993;100:393-8.
15. Krijnen JLM, Bogdanowicz JF, Seldenrijk CA, Mulder PGH, van der Kwast TH. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol 1997;158:171-4.
16. Bonkhoff H, Stein U, Remberger K. Multidirectional differentiation in the normal, hyerplastic, and neoplastic human prostate: simultaneous demonstration of cell specific epithelial markers. Hum Pathol 1994;25:42-6.
17. Ahlgren G, Pedersen K, Ludeberg S, Aus G, Hugosson J, Abrahamsson PA. Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment. Prostate 2000;42:274-9.
18. Van de Voorde WM, Elgamal AA, Van Poppel HP, Verbeken EK, Baert LV, Lauweryns JM. Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy. A comparative study of radical prostatectomies. Cancer 1994;74:3164-75.
19. Weinstein MH, Partin AW, Veltri RW, Epstein JL. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol 1996;27:683-7.
20. Cohen MK, Arber DA, Coffield KS, Keegan GT, McClintock J, Speights VO Jr. Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression. Cancer 1994;74:1899-903.
21. Epstein JL, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following radical prostatectomy. Am J Surg Pathol 1996;20:286-92.
22. Isshiki S, Akakura K, Komiya A, Suzuki H, Kamiya N, Ito H. Chromogranin A concentration as serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol 2002;167:512-5.
23. Sciarra A, Mariotti G, Gentile V, Voria G, Pastore S, Monti S et al. Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable? BJU Int 2003;91:438-45.